To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A

Who May Qualify: 1. Understand the purpose and risks of the study and provide willing to sign a consent form in accordance with national and local privacy laws: 2. Subject must be male, aged \>18 years old at the time of signing willing to sign a consent form, and ≤65 years old: 3. Participants with confirmed hemophilia A in their pre-admission history and based on clinical laboratory examination ; 4. Subjects had used FVIII products for at least 150 exposure days (ED) before enrollment; 5. Subject has no prior history of FVIII inhibitors; 6. Subjects agree to use a reliable barrier contraceptive method from the date of signing the willing to sign a consent form 7. Subject is willing and able to follow planned visits, treatment plans, and other study procedures. Who Should NOT Join This Trial: 1. The subject has any hemorrhagic disorder not related to hemophilia A, 2. Abnormal liver function test results of subjects during screening. 3. Abnormal laboratory examination of subjects during screening 4. The subject has acute or chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV) infection; Or are receiving antiviral treatment for hepatitis B and C; 5. Active systemic immune disease. Always talk to your doctor about whether this trial is right for you.